Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty

Abstract

Purpose Our aim was to evaluate the effectiveness of two different dosing regimens of human recombinant erythropoietin (rHu-EPO) for preoperative autologous blood collection in patients undergoing total hip arthroplasty (THA). Methods Prospective randomised trials in which erythropoietin 15,000 IU was administered intravenously twice a week or 30,000 IU once a week (total 90,000 IU) combined with ferrous II sulphate (Ferro-Gradumet 2) orally and compared with Ferro-Gradumet 2 alone. Results Although different dosing regimens of rHu-EPO administration during preoperative autologous blood donation have similar effects on the collection of two units of autologous blood, preoperative haemoglobin level and perioperative allogenic blood transfusion, a once weekly dose regimen of rHu-EPO was more convenient (although not statistically significantly) for patients. Conclusion We recommend the more practical and comfortable but yet highly effective therapeutic regimen with a single weekly intravenous administration of rHu-EPO for patients scheduled for THA.

Safety and cardiovascular effects of mineralocorticoid receptor antagonists for patients receiving hemodialysis: a systematic review and meta-analysis

“…We employed Revman 5.3 software (the Cochrane Collaboration, UK) 19 to perform the meta-analysis to estimate the serum potassium level after intervention. The results were presented as the mean difference with 95% confidence intervals.…”

A comprehensive review of the neonatal Fc receptor and its application in drug delivery

“…The protein is modified with three N-linked oligosaccharide chains (Asn24, Asn38 and Asn83) and one O-linked oligosaccharide chain, and the terminal sialic acid contents of the N-linked oligosaccharide chains affect the serum half-life and in vivo activity (Ser126) (Elliott et al, 2004(Elliott et al, , 2003Penno et al, 2010). Recombinant human EPO has been widely used in the treatment of anemia associated with chronic renal failure (Salgado et al, 2015), cancer chemotherapy (Vazquez-Mellado et al, 2015), HIV infection (Sullivan et al, 2011), allogeneic blood transfusions prior to planned surgery (Buljan et al, 2012), and a number of other pathological conditions (John et al, 2012;Joyeux-Faure, 2007;Sharples et al, 2006). Currently, EPO administration consists on an intravenous or subcutaneous injection, in order to increase the hemoglobin levels and to reduce the need for blood transfusions in the pathological states abovementioned .…”

Effectiveness of an autologous transfusion system following cemented and non-cemented revisions of total hip arthroplasty

“…Some authors recommended pre-operative blood donation [14], correction of preoperative anaemia [15], autologous donation and retransfusion systems [10,[16][17][18][19][20][21][22][23], supplementation of erythropoietin or iron [24,25], pharmacologic agents like tranexamic acid [26,27], plasmapheresis, normovolaemic haemodilution [28][29][30][31] and post-operative red blood cell salvage [32].…”